Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional.

Prezentacja na temat: "Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional."— Zapis prezentacji:

1 Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study  J. Styczynski, K. Czyzewski, M. Wysocki, O. Gryniewicz-Kwiatkowska, A. Kolodziejczyk-Gietka, M. Salamonowicz, L. Hutnik, O. Zajac- Spychala, A. Zaucha-Prazmo, L. Chelmecka-Wiktorczyk, K. Siewiera, J. Fraczkiewicz, Z. Malas, R. Tomaszewska, N. Irga-Jaworska, M. Plonowski, T. Ociepa, F. Pierlejewski, Z. Gamrot, A. Urbanek-Dadela, J. Gozdzik, W. Stolpa, B. Dembowska-Baginska, D. Perek, M. Matysiak, J. Wachowiak, J. Kowalczyk, W. Balwierz, K. Kalwak, A. Chybicka, W. Badowska, T. Szczepanski, E. Drozynska, M. Krawczuk-Rybak, T. Urasinski, W. Mlynarski, M. Woszczyk, G. Karolczyk, G. Sobol-Milejska, L. Gil  Clinical Microbiology and Infection  Volume 22, Issue 2, Pages 179.e1-179.e10 (February 2016) DOI: /j.cmi Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2 Fig. 1 Cumulative incidence of bacterial, fungal and viral in PHO and HSCT settings: (a) PHO patients; (b) all HSCT patients; (c) auto-HSCT; (d) allo-HSCT; (e) bacterial infections, HSCT vs. PHO; (f) viral infections, HSCT vs. PHO; (g) proven/probable/possible fungal infections; HSCT vs. PHO; (h) proven/probable fungal infections, HSCT vs. PHO. HSCT, hematopoietic stem cell transplantation; PHO, paediatric haematology and oncology. Clinical Microbiology and Infection  , 179.e1-179.e10DOI: ( /j.cmi ) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3 Fig. 2 IFD in PHO (a–d) and HSCT (e–h) patients: (a) cumulative incidence in all PHO patients; (b) cumulative incidence in AML and ALL patients; (c) survival from IFD in PHO patients; (d) survival from IFD with respect to the level of diagnosis in PHO patients; (e) cumulative incidence in all HSCT patients; (f) cumulative incidence in allo- and auto-HSCT patients; (g) cumulative incidence in AML and ALL patients after HSCT; (h) survival from IFD with respect to level of diagnosis after HSCT. ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; HSCT, haematopoietic stem cell transplantation; IFD, invasive fungal disease; PHO, paediatric haematology and oncology. Clinical Microbiology and Infection  , 179.e1-179.e10DOI: ( /j.cmi ) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions